CD79A and Miyoshi myopathy: At the clinical level, patients with IgA MM exhibit a higher incidence of t(4;14) (40% in IgA versus 13% in IgG), shorter progression-free survival (PFS) and worse overall survival (OS) compared to patients with IgG MM (15, 16).